vs
Sprout Social, Inc.（SPT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Sprout Social, Inc.的1.1倍（$127.1M vs $120.9M），再鼎医药同比增速更快（17.1% vs 12.9%），Sprout Social, Inc.自由现金流更多（$9.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 11.8%）
Sprout Social, Inc.是一家提供社交媒体管理平台服务的科技企业，由贾斯汀·霍华德等四位创始人在2010年成立，总部位于美国芝加哥，目前是一家上市企业。其推出的平台能够帮助企业统一管理多渠道社媒账号，开展营销互动与数据分析工作。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SPT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$120.9M
营收增速更快
ZLAB
高出4.2%
12.9%
自由现金流更多
SPT
多$36.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
11.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.9M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 77.6% | 51.0% |
| 营业利润率 | -9.0% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 12.9% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.18 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SPTZLAB
| Q4 25 | $120.9M | $127.1M | ||
| Q3 25 | $115.6M | $115.4M | ||
| Q2 25 | $111.8M | $109.1M | ||
| Q1 25 | $109.3M | $105.7M | ||
| Q4 24 | $107.1M | $108.5M | ||
| Q3 24 | $102.6M | $101.8M | ||
| Q2 24 | $99.4M | $100.1M | ||
| Q1 24 | $96.8M | $87.1M |
净利润SPTZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-9.4M | $-36.0M | ||
| Q2 25 | $-12.0M | $-40.7M | ||
| Q1 25 | $-11.2M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.1M | $-41.7M | ||
| Q2 24 | $-16.9M | $-80.3M | ||
| Q1 24 | $-13.6M | $-53.5M |
毛利率SPTZLAB
| Q4 25 | 77.6% | 51.0% | ||
| Q3 25 | 77.7% | 59.5% | ||
| Q2 25 | 77.7% | 60.6% | ||
| Q1 25 | 77.3% | 63.6% | ||
| Q4 24 | 78.1% | 61.5% | ||
| Q3 24 | 77.4% | 64.1% | ||
| Q2 24 | 77.5% | 64.9% | ||
| Q1 24 | 76.8% | 61.4% |
营业利润率SPTZLAB
| Q4 25 | -9.0% | -54.6% | ||
| Q3 25 | -7.9% | -42.3% | ||
| Q2 25 | -11.0% | -50.3% | ||
| Q1 25 | -10.2% | -53.3% | ||
| Q4 24 | -12.8% | -62.6% | ||
| Q3 24 | -16.4% | -66.6% | ||
| Q2 24 | -16.6% | -76.0% | ||
| Q1 24 | -13.7% | -80.7% |
净利率SPTZLAB
| Q4 25 | — | — | ||
| Q3 25 | -8.1% | -31.2% | ||
| Q2 25 | -10.7% | -37.3% | ||
| Q1 25 | -10.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -16.6% | -40.9% | ||
| Q2 24 | -17.0% | -80.2% | ||
| Q1 24 | -14.0% | -61.4% |
每股收益（稀释后）SPTZLAB
| Q4 25 | $-0.18 | $-0.05 | ||
| Q3 25 | $-0.16 | $-0.03 | ||
| Q2 25 | $-0.21 | $-0.04 | ||
| Q1 25 | $-0.19 | $-0.04 | ||
| Q4 24 | $-0.25 | $-0.09 | ||
| Q3 24 | $-0.30 | $-0.04 | ||
| Q2 24 | $-0.30 | $-0.08 | ||
| Q1 24 | $-0.24 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.3M | $689.6M |
| 总债务越低越好 | $40.0M | — |
| 股东权益账面价值 | $203.4M | $715.5M |
| 总资产 | $523.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资SPTZLAB
| Q4 25 | $95.3M | $689.6M | ||
| Q3 25 | $90.6M | $717.2M | ||
| Q2 25 | $101.5M | $732.2M | ||
| Q1 25 | $100.9M | $757.3M | ||
| Q4 24 | $86.4M | $779.7M | ||
| Q3 24 | $82.9M | $616.1M | ||
| Q2 24 | $80.9M | $630.0M | ||
| Q1 24 | $69.2M | $650.8M |
总债务SPTZLAB
| Q4 25 | $40.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $25.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SPTZLAB
| Q4 25 | $203.4M | $715.5M | ||
| Q3 25 | $194.1M | $759.9M | ||
| Q2 25 | $184.6M | $791.7M | ||
| Q1 25 | $175.3M | $810.8M | ||
| Q4 24 | $166.6M | $840.9M | ||
| Q3 24 | $158.1M | $667.7M | ||
| Q2 24 | $152.1M | $704.2M | ||
| Q1 24 | $147.3M | $762.2M |
总资产SPTZLAB
| Q4 25 | $523.1M | $1.2B | ||
| Q3 25 | $481.4M | $1.2B | ||
| Q2 25 | $422.9M | $1.2B | ||
| Q1 25 | $424.7M | $1.2B | ||
| Q4 24 | $428.3M | $1.2B | ||
| Q3 24 | $388.8M | $985.3M | ||
| Q2 24 | $393.6M | $987.4M | ||
| Q1 24 | $389.9M | $988.4M |
负债/权益比SPTZLAB
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $9.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 8.2% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $39.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SPTZLAB
| Q4 25 | $10.9M | $-26.0M | ||
| Q3 25 | $9.3M | $-32.0M | ||
| Q2 25 | $5.1M | $-31.0M | ||
| Q1 25 | $18.1M | $-61.7M | ||
| Q4 24 | $4.1M | $-55.8M | ||
| Q3 24 | $9.0M | $-26.8M | ||
| Q2 24 | $2.1M | $-42.2M | ||
| Q1 24 | $11.2M | $-90.1M |
自由现金流SPTZLAB
| Q4 25 | $9.9M | $-26.7M | ||
| Q3 25 | $8.5M | $-35.0M | ||
| Q2 25 | $4.2M | $-33.9M | ||
| Q1 25 | $16.7M | $-63.2M | ||
| Q4 24 | $3.3M | $-58.4M | ||
| Q3 24 | $8.5M | $-28.2M | ||
| Q2 24 | $1.6M | $-42.9M | ||
| Q1 24 | $10.1M | $-91.1M |
自由现金流率SPTZLAB
| Q4 25 | 8.2% | -21.0% | ||
| Q3 25 | 7.4% | -30.4% | ||
| Q2 25 | 3.7% | -31.1% | ||
| Q1 25 | 15.3% | -59.9% | ||
| Q4 24 | 3.0% | -53.8% | ||
| Q3 24 | 8.3% | -27.7% | ||
| Q2 24 | 1.6% | -42.9% | ||
| Q1 24 | 10.4% | -104.5% |
资本支出强度SPTZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 1.2% | 1.5% | ||
| Q4 24 | 0.8% | 2.4% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.5% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SPT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
